CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Bristol-Myers Squibb Co - BMY CFD

73.59
1.13%
0.18
Low: 73.02
High: 74
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.18
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Bristol-Myers Squibb Co ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 74.43
Open* 73.75
1-Year Change* 11.64%
Day's Range* 73.02 - 74
52 wk Range 65.60-81.44
Average Volume (10 days) 8.67M
Average Volume (3 months) 183.43M
Market Cap 158.44B
P/E Ratio 25.25
Shares Outstanding 2.13B
Revenue 46.16B
EPS 2.95
Dividend (Yield %) 3.05958
Beta 0.44
Next Earnings Date Apr 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 7, 2023 74.43 0.36 0.49% 74.07 74.61 73.90
Feb 6, 2023 74.45 0.03 0.04% 74.42 75.09 73.98
Feb 3, 2023 74.35 1.78 2.45% 72.57 74.38 72.34
Feb 2, 2023 72.66 2.68 3.83% 69.98 72.80 69.32
Feb 1, 2023 71.10 -1.20 -1.66% 72.30 72.76 69.93
Jan 31, 2023 72.58 0.95 1.33% 71.63 72.58 71.56
Jan 30, 2023 71.96 -0.32 -0.44% 72.28 72.82 71.77
Jan 27, 2023 72.37 -0.20 -0.28% 72.57 73.37 72.19
Jan 26, 2023 72.90 0.30 0.41% 72.60 73.11 71.83
Jan 25, 2023 73.07 0.68 0.94% 72.39 73.16 71.79
Jan 24, 2023 72.28 -0.48 -0.66% 72.76 73.38 71.93
Jan 23, 2023 73.15 -0.78 -1.06% 73.93 74.11 72.73
Jan 20, 2023 74.07 0.30 0.41% 73.77 74.07 73.22
Jan 19, 2023 73.67 2.24 3.14% 71.43 73.79 71.43
Jan 18, 2023 72.07 0.11 0.15% 71.96 72.59 71.07
Jan 17, 2023 72.23 -0.67 -0.92% 72.90 73.38 71.91
Jan 13, 2023 72.42 0.92 1.29% 71.50 72.44 71.23
Jan 12, 2023 71.53 0.08 0.11% 71.45 71.86 70.93
Jan 11, 2023 71.85 0.38 0.53% 71.47 71.90 70.79
Jan 10, 2023 71.58 0.44 0.62% 71.14 71.62 70.57

Bristol-Myers Squibb Co Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 19427 20776 22561 26145 42518 46385
Revenue 19427 20776 22561 26145 42518 46385
Cost of Revenue, Total 4925 5917 6436 7804 11133 9601
Gross Profit 14502 14859 16125 18341 31385 36784
Total Operating Expense 13480 15532 16175 19758 49365 37770
Selling/General/Admin. Expenses, Total 4911 4687 4550 4870 7733 7688
Research & Development 4927 4823 5052 5845 9519 9532
Depreciation / Amortization 21 3 41 1206 9688 10023
Unusual Expense (Income) -585 1453 1449 1393 12819 2659
Other Operating Expenses, Total -719 -1351 -1353 -1360 -1527 -1733
Operating Income 5947 5244 6386 6387 -6847 8615
Interest Income (Expense), Net Non-Operating 15 33 -380 -69 -71 -550
Other, Net -47 -146 -38 -1343 47 33
Net Income Before Taxes 5915 5131 5968 4975 -6871 8098
Net Income After Taxes 4507 3871 5003 3460 -8995 7014
Minority Interest -50 32 -27 -21 -20 -20
Net Income Before Extra. Items 4457 3903 4976 3439 -9015 6994
Net Income 4457 1007 4920 3439 -9015 6994
Income Available to Common Excl. Extra. Items 4457 3903 4976 3439 -9015 6994
Income Available to Common Incl. Extra. Items 4457 1007 4920 3439 -9015 6994
Diluted Net Income 4457 1007 4920 3439 -9015 6994
Diluted Weighted Average Shares 1680 1652 1637 1712 2258 2245
Diluted EPS Excluding Extraordinary Items 2.65298 2.36259 3.03971 2.00876 -3.99247 3.11537
Dividends per Share - Common Stock Primary Issue 1.52 1.56 1.6 1.64 1.8 1.96
Diluted Normalized EPS 2.38949 3.03729 3.78174 2.58034 -0.19982 3.81069
Total Extraordinary Items -2896 -56 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 11073 11703 11624 11985 11648
Revenue 11073 11703 11624 11985 11648
Cost of Revenue, Total 2503 2451 2291 2356 2471
Gross Profit 8570 9252 9333 9629 9177
Total Operating Expense 8812 9988 9628 9342 9095
Selling/General/Admin. Expenses, Total 1667 1882 1787 2352 1829
Research & Development 2225 2261 2440 2607 2220
Depreciation / Amortization 2513 2547 2546 2417 2417
Unusual Expense (Income) 271 1252 989 146 635
Other Operating Expenses, Total -367 -405 -425 -536 -477
Operating Income 2261 1715 1996 2643 2553
Interest Income (Expense), Net Non-Operating 257 -170 149 -786 -960
Other, Net 12 8 12 1 94
Net Income Before Taxes 2530 1553 2157 1858 1687
Net Income After Taxes 2029 1061 1552 2372 1283
Minority Interest -8 -6 -6 0 -5
Net Income Before Extra. Items 2021 1055 1546 2372 1278
Net Income 2021 1055 1546 2372 1278
Income Available to Common Excl. Extra. Items 2021 1055 1546 2372 1278
Income Available to Common Incl. Extra. Items 2021 1055 1546 2372 1278
Diluted Net Income 2021 1055 1546 2372 1278
Diluted Weighted Average Shares 2265 2252 2243 2221 2164
Diluted EPS Excluding Extraordinary Items 0.89227 0.46847 0.68926 1.06799 0.59057
Dividends per Share - Common Stock Primary Issue 0.49 0.49 0.49 0.49 0.54
Diluted Normalized EPS 0.89007 0.85213 1.0486 1.02071 0.81817
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 13704 14854 17160 29354 30192 33262
Cash and Short Term Investments 6350 6812 8884 15393 15831 16966
Cash & Equivalents 4237 5421 6911 12346 14546 13979
Short Term Investments 2113 1391 1973 3047 1285 2987
Total Receivables, Net 4916 5609 5747 7685 8501 9369
Accounts Receivable - Trade, Net 3774 4347 4636 6476 7219 7979
Total Inventory 1241 1166 1195 4293 2074 2095
Prepaid Expenses 627 691 218 754 1799 2786
Other Current Assets, Total 570 576 1116 1229 1987 2046
Total Assets 33707 33551 34986 129944 118481 109314
Property/Plant/Equipment, Total - Net 4980 5001 5027 6956 6745 6968
Property/Plant/Equipment, Total - Gross 9173 8987 8845 10911 10330 11001
Accumulated Depreciation, Total -4193 -3986 -3818 -3955 -3585 -4033
Goodwill, Net 6875 6863 6538 22488 20547 20502
Intangibles, Net 1385 1210 1091 63969 53243 42527
Long Term Investments 2719 2480 1775 4601 4509 2713
Other Long Term Assets, Total 4044 3143 3395 2576 3245 3342
Total Current Liabilities 8841 9563 10654 18304 19080 21868
Accounts Payable 1664 2248 1892 2445 2713 2949
Accrued Expenses 4587 5313 5687 8100 9582 10104
Notes Payable/Short Term Debt 243 987 454 583 340 184
Current Port. of LT Debt/Capital Leases 749 0 1249 2763 2000 4764
Other Current Liabilities, Total 1598 1015 1372 4413 4445 3867
Total Liabilities 17530 21810 20955 78346 80659 73368
Total Long Term Debt 5716 6975 5646 43387 48336 39605
Long Term Debt 5716 6975 5646 43387 48336 39605
Minority Interest 170 106 96 100 60 60
Other Liabilities, Total 2803 5166 4559 10101 7776 7334
Total Equity 16177 11741 14031 51598 37822 35946
Preferred Stock - Non Redeemable, Net 0 0 0 0 0 0
Common Stock 221 221 221 292 292 292
Additional Paid-In Capital 1725 1898 2081 43709 44325 44361
Retained Earnings (Accumulated Deficit) 33513 31160 34065 34474 21281 23820
Treasury Stock - Common -16779 -19249 -19574 -25357 -26237 -31259
Unrealized Gain (Loss) -7 32 -30 6 11 2
Other Equity, Total -2496 -2321 -2732 -1526 -1850 -1270
Total Liabilities & Shareholders’ Equity 33707 33551 34986 129944 118481 109314
Total Common Shares Outstanding 1664 1625 1624 2228 2221 2153
Total Preferred Shares Outstanding 0.00413 0.00407
Deferred Income Tax 6454 5407 4501
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 27111 29161 31443 33262 30121
Cash and Short Term Investments 12930 14016 15823 16966 14968
Cash & Equivalents 10982 11024 13540 13979 12369
Short Term Investments 1948 2992 2283 2987 2599
Total Receivables, Net 8660 11275 11738 9369 8511
Accounts Receivable - Trade, Net 7187 7713 7878 7979 7156
Total Inventory 1953 2137 2163 2095 2104
Other Current Assets, Total 3568 1733 1719 2046 4538
Total Assets 112435 110797 110893 109314 103034
Property/Plant/Equipment, Total - Net 6613 6801 6835 6968 6941
Property/Plant/Equipment, Total - Gross 10243 10639 10805 11001 11109
Accumulated Depreciation, Total -3630 -3838 -3970 -4033 -4168
Goodwill, Net 20524 20529 20519 20502 20500
Intangibles, Net 50819 48065 44930 42527 40103
Long Term Investments 4636 3765 4784 2713 2185
Other Long Term Assets, Total 2732 2476 2382 3342 3184
Total Current Liabilities 17330 18991 21460 21868 22821
Accounts Payable 2972 3609 2695 2949 2944
Accrued Expenses 8491 8962 9971 10104 8319
Notes Payable/Short Term Debt 277 158 296 184 225
Current Port. of LT Debt/Capital Leases 1500 2497 4769 4764 7297
Other Current Liabilities, Total 4090 3765 3729 3867 4036
Total Liabilities 74830 73989 73680 73368 71454
Total Long Term Debt 44505 42503 39677 39605 37450
Long Term Debt 44505 42503 39677 39605 37450
Deferred Income Tax 5235 4931 4956 4501 3809
Minority Interest 68 66 71 60 65
Other Liabilities, Total 7692 7498 7516 7334 7309
Total Equity 37605 36808 37213 35946 31580
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 292 292 292 292 292
Additional Paid-In Capital 43852 44064 44292 44361 43756
Retained Earnings (Accumulated Deficit) 22204 22168 22625 23820 23948
Treasury Stock - Common -27199 -28198 -28572 -31259 -35187
Unrealized Gain (Loss) 9 7 4 2 1
Other Equity, Total -1553 -1525 -1428 -1270 -1230
Total Liabilities & Shareholders’ Equity 112435 110797 110893 109314 103034
Total Common Shares Outstanding 2232.84 2222.11 2219.65 2153 2129.06
Prepaid Expenses 2786
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 4507 975 4947 3460 -8995 7014
Cash From Operating Activities 3058 5275 5940 8067 14052 16207
Cash From Operating Activities 382 789 637 1746 10380 10686
Deferred Taxes -204 1010 86 -924 983 -1393
Non-Cash Items -475 913 94 720 10701 1153
Cash Taxes Paid 2000 546 747 1503 3400 3500
Cash Interest Paid 191 215 212 414 1600 1500
Changes in Working Capital -1152 1588 176 3065 983 -1253
Cash From Investing Activities 1480 -66 -874 -9770 -10859 -538
Capital Expenditures -1215 -1055 -951 -836 -753 -973
Other Investing Cash Flow Items, Total 2695 989 77 -8934 -10106 435
Cash From Financing Activities -2653 -4077 -3535 7621 -1151 -16224
Financing Cash Flow Items 15 -22 -54 -53 542 641
Total Cash Dividends Paid -2547 -2577 -2613 -2679 -4075 -4396
Issuance (Retirement) of Stock, Net -231 -2469 -320 -7300 -1546 -6287
Issuance (Retirement) of Debt, Net 110 991 -548 17653 3928 -6182
Foreign Exchange Effects -33 52 -41 -9 111 -102
Net Change in Cash 1852 1184 1490 5909 2153 -657
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 2029 3090 4642 7014 1283
Cash From Operating Activities 3824 6884 12150 16207 3812
Cash From Operating Activities 2668 5380 8107 10686 2584
Deferred Taxes 68 -95 -127 -1393 -687
Non-Cash Items -507 356 725 1153 994
Changes in Working Capital -434 -1847 -1197 -1253 -362
Cash From Investing Activities -143 37 -939 -538 95
Capital Expenditures -173 -383 -653 -973 -253
Other Investing Cash Flow Items, Total 30 420 -286 435 348
Cash From Financing Activities -7295 -10477 -12257 -16224 -5653
Financing Cash Flow Items 172 448 644 641 333
Total Cash Dividends Paid -1108 -2207 -3297 -4396 -1185
Issuance (Retirement) of Stock, Net -1775 -3011 -3536 -6287 -5000
Issuance (Retirement) of Debt, Net -4584 -5707 -6068 -6182 199
Foreign Exchange Effects -38 -20 -48 -102 9
Net Change in Cash -3652 -3576 -1094 -657 -1737
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.3545 198890804 3066015 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.2989 112662905 2240471 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.3424 92325898 -602471 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 3.0052 63894939 526421 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 2.9555 62838772 -1753198 2022-09-30 LOW
Capital International Investors Investment Advisor 2.4644 52396432 14298520 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8412 39147135 1131303 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.5702 33385956 -2374239 2022-09-30 LOW
BofA Global Research (US) Research Firm 1.0777 22914303 1075724 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0666 22677818 -372517 2021-12-31 LOW
Managed Account Advisors LLC Investment Advisor 1.0476 22273448 -2068389 2022-09-30 LOW
PRIMECAP Management Company Investment Advisor 1.0412 22137675 -74030 2022-09-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 0.9424 20037642 -147066 2022-09-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 0.789 16775562 -1577777 2022-09-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7761 16501572 -551586 2022-09-30 LOW
Nuveen LLC Pension Fund 0.7673 16313175 698391 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7056 15001848 -146955 2022-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.6895 14659982 155845 2022-09-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.6759 14370082 -23245 2022-09-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.6643 14124064 -3100460 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+500000+

Traders

93000+

Active clients monthly

$57000000+

Monthly investing volume

$31000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Bristol-Myers Squibb Company profile

What is Bristol-Myers Squibb Co.?

The Bristol-Myers Squibb Company is an international biopharmaceutical company specialising in discovering, developing and delivering innovative biopharmaceutical products and medicines to patients who suffer from serious diseases. Bristol-Myers Squibb provides medicines to help people fight cancer, hepatitis B and C, cardiovascular disease, HIV and AIDS. The company supplies its products to retail and wholesale pharmacies, governmental entities, and hospitals throughout the world.
 

What’s the history behind the company?

1858 – The Squibb corporation is founded by Edward Robinson Squibb in New York.
 
1887 – The Clinton Pharmaceutical company i purchased by William McLaren Bristol and John Ripley Myers. Two years later they rename it as “Bristol, Myers and Company”, and later, following Myers death in 1899 as the “Bristol-Myers Corporation”.
 
1903 – Sal Hepatica, a laxative salt is developed and released marking the first product for the company.
 
1943 – Acquisition of Cheplin Biological Laboratories, Bristol laboratories in 1945 creating antibiotics, is met with competition from Squibbs.
 
1989 – Bristol-Myers merges with Squibb to form Bristol-Myers Squibb, creating one of the world’s largest pharmaceutical companies.
 
1998 – Development of Excedrin Migraine, one of the first migraine medications available without a prescription in the US.
 
2004 – Bristol-Myers Squibb pays $150 million in a settlement for accounting fraud, the company does not admit or deny guilt. In 2006, the company is hit again by charges and pays $2.1 million to the Federal Trade Commission.
 
2008 – The company undertakes a number of partnerships, including therapy for cardiovascular diseases with KAI pharmaceuticals, cancer therapies with Kosan, and two novel therapies for cancer with Exelixis. These collaborations continue into 2009 with more added.
 
2010 – Lamberto Andreotti took over as CEO of Bristol-Myers Squibb. By 2012, the company’s net sales reach $17.6 billion.
 
2015 – Dr. Giovanni Caforio becomes the head of the company.
 

About the company

Bristol-Myers Squibb operates worldwide with locations such as Asia, including China and Japan, Southeast Asia in Bangalore India, across Europe in Belgium, England, France, Ireland and Italy, and North America. This includes a number of research and development facilities, vital to the creation of new pharmaceutical products.
 
Across its facilities, the company employs approximately 23,700 people. To date, Dr. Giovanni Caforio is the Chairman and CEO of the company with Charles Bancroft as CFO.
 
The company has numerous awards and achievements, including 2018 Best-of-the-Best Corporations for Inclusion by National Business Inclusion Consortium, Fortune’s World’s Most Admired Companies, Dow Jones' 2017 North American Index of Leading Sustainable Companies, and Forbes America’s Best Employers for 2016.
 

Key Statistics

  • Revenue in 2017 – $20.78 billion
  • Net income in 2017 – $975 million
  • Total assets in 2017 – 33.55 billion
  • Total equity in 2017 – 11.85 billion

Major acquisitions

  • Adnexus Therapeutics – 2007
  • Kosan Biosciences – 2008
  • Medarex – 2009
  • ZymoGenetics – 2010
  • Amira Pharmaceuticals – 2011
  • Inhibitex Inc. – 2012
  • Amylin Pharmaceuticals and AstraZeneca – 2018
  • iPierian – 2014
  • Flexus Biosciences – 2015
  • Cardioxyl – 2015
  • Padlock Therapeutics – 2016
  • Cormorant Pharmaceuticals – 2016
  • IFM Therapeutics – 2017

Where is Bristol-Myers Squibb Co. traded?

Bristol-Myers Squibb is traded on the New York Stock Exchange (NYSE) under the ticker BMY. It is also a component of the S&P 100 and S&P 500. Trade the latest Bristol-Myers Squibb share price with Capital.com, explore the most up-to-date BMY charts, and delve into this pharmaceutical company.
Industry: Pharmaceuticals (NEC)

430 E. 29Th Street
14 Floor
NEW YORK
NEW YORK 10016
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

78.77 Price
+1.220% 1D Chg, %
Long position overnight fee -0.0163%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

12,537.30 Price
-1.260% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0077%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.40 Price
-1.120% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00372

Natural Gas

2.47 Price
-6.290% 1D Chg, %
Long position overnight fee -0.1217%
Short position overnight fee 0.0860%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading